[
  {
    "ts": null,
    "headline": "Top Analyst Reports for Applied Materials, Linde & Abbott",
    "summary": "AMAT rides a semiconductor rebound as systems, services and ICAPS drive gains, even as China export curbs, memory lag and costs cloud near-term growth.",
    "url": "https://finnhub.io/api/news?id=4882983f3f2aea30485b4b4038b830f3d3f988a38704c55daaedfe8907fbe63b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769725140,
      "headline": "Top Analyst Reports for Applied Materials, Linde & Abbott",
      "id": 138302017,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "AMAT rides a semiconductor rebound as systems, services and ICAPS drive gains, even as China export curbs, memory lag and costs cloud near-term growth.",
      "url": "https://finnhub.io/api/news?id=4882983f3f2aea30485b4b4038b830f3d3f988a38704c55daaedfe8907fbe63b"
    }
  },
  {
    "ts": null,
    "headline": "These Are the 3 Top Oversold S&P 500 Stocks. Should You Buy the Dip?",
    "summary": "Abbott, Roper, and Humana are three blue-chip oversold stocks with significant upside potential for shareholders in January 2026.",
    "url": "https://finnhub.io/api/news?id=0254a96164f3a1ba53460a608a032ff657dccd8acfab195e1c724d54ba2f9c58",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769689802,
      "headline": "These Are the 3 Top Oversold S&P 500 Stocks. Should You Buy the Dip?",
      "id": 138295686,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott, Roper, and Humana are three blue-chip oversold stocks with significant upside potential for shareholders in January 2026.",
      "url": "https://finnhub.io/api/news?id=0254a96164f3a1ba53460a608a032ff657dccd8acfab195e1c724d54ba2f9c58"
    }
  },
  {
    "ts": null,
    "headline": "10 Highest Rated Dividend Kings For Generations Of Income",
    "summary": "Top 10 Dividend Kings ranked for reliability, dividend safety, and valueâfeaturing ABM and strict payout screens. Click for the income picks!",
    "url": "https://finnhub.io/api/news?id=06c075c19b76a9c2cc4f93a4b1963260b9df1dbd4fb5f8bc4fd89bab28aafc14",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769681421,
      "headline": "10 Highest Rated Dividend Kings For Generations Of Income",
      "id": 138295281,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1411467903/image_1411467903.jpg?io=getty-c-w1536",
      "related": "ABT",
      "source": "SeekingAlpha",
      "summary": "Top 10 Dividend Kings ranked for reliability, dividend safety, and valueâfeaturing ABM and strict payout screens. Click for the income picks!",
      "url": "https://finnhub.io/api/news?id=06c075c19b76a9c2cc4f93a4b1963260b9df1dbd4fb5f8bc4fd89bab28aafc14"
    }
  },
  {
    "ts": null,
    "headline": "5 Insightful Analyst Questions From Abbott Laboratories’s Q4 Earnings Call",
    "summary": "Abbott Laboratories ended the fourth quarter with sales growth below Wall Street’s expectations, driven primarily by ongoing challenges in its nutrition segment. Management attributed this underperformance to price-driven volume declines, particularly following the loss of a major U.S. WIC contract and ongoing consumer price sensitivity. CEO Robert Ford acknowledged the need for a shift, stating, “This path is not sustainable long-term, so we began to make changes in the fourth quarter.” The com",
    "url": "https://finnhub.io/api/news?id=cb060ac815166437e1fbf9feb6592161a8f648cee641ddb3645133ef0630b12e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769664824,
      "headline": "5 Insightful Analyst Questions From Abbott Laboratories’s Q4 Earnings Call",
      "id": 138297215,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories ended the fourth quarter with sales growth below Wall Street’s expectations, driven primarily by ongoing challenges in its nutrition segment. Management attributed this underperformance to price-driven volume declines, particularly following the loss of a major U.S. WIC contract and ongoing consumer price sensitivity. CEO Robert Ford acknowledged the need for a shift, stating, “This path is not sustainable long-term, so we began to make changes in the fourth quarter.” The com",
      "url": "https://finnhub.io/api/news?id=cb060ac815166437e1fbf9feb6592161a8f648cee641ddb3645133ef0630b12e"
    }
  },
  {
    "ts": null,
    "headline": "Q3 Earnings Highs And Lows: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks",
    "summary": "As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including AbbVie (NYSE:ABBV) and its peers.",
    "url": "https://finnhub.io/api/news?id=16a3e05644a2e9488b220bfcd85a672214927ef35a68d48fb8882ffa27264901",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769657557,
      "headline": "Q3 Earnings Highs And Lows: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks",
      "id": 138302008,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including AbbVie (NYSE:ABBV) and its peers.",
      "url": "https://finnhub.io/api/news?id=16a3e05644a2e9488b220bfcd85a672214927ef35a68d48fb8882ffa27264901"
    }
  }
]